Log in

NASDAQ:ARAY - Accuray Stock Price, Forecast & News

$3.32
-0.05 (-1.48 %)
(As of 02/23/2020 02:54 AM ET)
Today's Range
$3.31
Now: $3.32
$3.39
50-Day Range
$2.60
MA: $3.40
$4.28
52-Week Range
$2.35
Now: $3.32
$5.40
Volume298,718 shs
Average Volume739,538 shs
Market Capitalization$300.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$418.79 million
Book Value$0.62 per share

Profitability

Net Income$-16,430,000.00

Miscellaneous

Employees998
Market Cap$300.36 million
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.


Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) released its earnings results on Tuesday, January, 28th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.19. The medical equipment provider had revenue of $98.83 million for the quarter, compared to analyst estimates of $98.45 million. Accuray had a negative net margin of 0.30% and a negative return on equity of 23.59%. During the same quarter in the previous year, the business earned ($0.05) earnings per share. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Accuray.

What guidance has Accuray issued on next quarter's earnings?

Accuray updated its FY 2020 After-Hours earnings guidance on Tuesday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $412.77 million.

What price target have analysts set for ARAY?

2 brokerages have issued 12 month target prices for Accuray's stock. Their forecasts range from $4.00 to $9.50. On average, they anticipate Accuray's share price to reach $6.75 in the next year. This suggests a possible upside of 103.3% from the stock's current price. View Analyst Price Targets for Accuray.

What is the consensus analysts' recommendation for Accuray?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Accuray.

Has Accuray been receiving favorable news coverage?

News coverage about ARAY stock has been trending very negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Accuray earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Accuray.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Intel (INTC), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Tesla (TSLA), Abeona Therapeutics (ABEO) and Aduro BioTech (ADRO).

Who are Accuray's key executives?

Accuray's management team includes the folowing people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
  • Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.45%), Archon Capital Management LLC (4.82%), Heartland Advisors Inc. (3.88%), Russell Investments Group Ltd. (3.87%), Royce & Associates LP (2.31%) and State Street Corp (1.80%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Mackay Shields LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Oxford Asset Management LLP, State Street Corp, Bank of New York Mellon Corp and Algert Global LLC. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

Which major investors are buying Accuray stock?

ARAY stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Assenagon Asset Management S.A., Lapides Asset Management LLC, Royce & Associates LP, Barrow Hanley Mewhinney & Strauss LLC, California Public Employees Retirement System, Archon Capital Management LLC and Boston Partners. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $3.32.

How big of a company is Accuray?

Accuray has a market capitalization of $300.36 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

What is Accuray's official website?

The official website for Accuray is http://www.accuray.com/.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at investors.accuray.com.


MarketBeat Community Rating for Accuray (NASDAQ ARAY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel